Helper T Cell (CD4⁺) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity.

ABSTRACT: Antibody-mediated rejection (ABMR) is a major cause of dysfunction and loss of transplanted kidney. The current treatments for ABMR involve nonspecific inhibition and clearance of T/B cells or plasma cells. However, the prognosis of patients following current treatment is poor. T follicular helper cells (Tfh) play an important role in allograft-specific antibodies secreting plasma cell (PC) development. Tfh cells are therefore considered to be important therapeutic targets for the treatment of antibody hypersecretion disorders, such as transplant rejection and autoimmune diseases. Tacrolimus (Tac), the primary immunosuppressant, prevents rejection by reducing T cell activation. However, its administration should be closely monitored to avoid serious side effects. In this study, we investig

SUBMITTER: Shen J 

PROVIDER: S-EPMC9343082 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature